Stemcell Institute Inc.

Since its founding in 1999, Stemcell Institute Inc. has been engaged in R&D and services centered on the long-term storage of umbilical cord blood-derived stem cells. As a leading pioneer in the private cord blood bank industry, this institute's stem cells are helping support and advance new medical treatments and therapies. For instance, the storage of cord blood-derived stem cells is providing immediate benefits to the promising fields of regenerative medicine and cell therapy. These cells are being applied to treat intractable hematologic diseases such as leukemia and aplastic anemia as well as to develop treatments currently in their clinical trial or research phases. Our intimate network of obstetric care facilities and support system ensure that clients can trust our strict quality standards and reliable storage environments. Each year the scale of our storage operations continues to grow, and today, we hold a substantial 99% share of the domestic umbilical cord blood bank market. (*as of October 2018)

Strex Inc.

Strex Inc. is engaged in the research, development, and manufacture of laboratory systems. In addition to developing 3D culture systems for application in regenerative medicine and tissue engineering, Strex is engaged in the development, production and sale of assisted reproductive technology systems and Controlled-rate Freezers for effectively freezing iPS/ES cells.
By combining the Stemcell Institute's decades of experience in quality management and extensive expertise in stem cell storage with Strex's comprehensive knowledge of equipment for regenerative medicine and assisted reproduction, Trim is strengthening its operational foundation in both of these fields.